medac at the
EBMT 2022

Wedel, Germany (29.03.2022) Numerous data presented at the EMBT congress from prospective and retrospective studies demonstrate the benefits of treosulfan-based conditioning for both adult and paediatric patients.

This year, medac was once again in attendance at the congress of the European Society for Blood and Bone Marrow Transplantation (EMBT) with a virtual booth (https://www.trecondi-ebmt2022.com).  

Focus at the EBMT: treosulfan-based conditioning

One focus at this year’s EMBT was the presentation of the latest data on treosulfan-based conditioning. 14 of the abstracts and posters by various European study groups revealed the results of prospective and retrospective studies on treosulfan-based treatment. In three of six oral sessions data of medac sponsored studies have been presented.  

In his presentation, Prof. Dr. Karl-Walter Sykora (Germany) revealed the results of the randomised phase II study (MC-FludT.16/NM)¹, comparing treosulfan (Treo)- and busulfan(Bu)-based conditioning in paediatric patients with non-malignant diseases, for the first time. Conditioning treatment with treosulfan led to very good survival rates (overall survival after 12 months of Treo vs. Bu: 96.1% (90% CI: 88.0%; 98.8%) vs. 88.0% (90% CI: 77.9%; 93.7%)) with a lower rate of transplant-related mortality (TRM after 12 months of Treo vs. Bu: 3.9% (90% CI: 1.2%; 12.0%) vs. 12.0% (90% CI: 6.3%; 22.1%)).²  

In further two presentations, Prof. Dr. Matthias Stelljes (Germany) and Prof. Dr. Friedrich Stölzel (Germany) showed the results of subgroup analyses of the pivotal phase III study MC-FludT.14/L³ investigating the efficacy of treosulfan for the respective indications. The data confirmed the clinically relevant survival benefits of treosulfan-based conditioning both for older and/or comorbid patients with MDS, as well as for the respective patient cohort with AML, in comparison with busulfan-based therapy.^4,5  

Along with the results of the prospective studies, numerous retrospective analyses were also presented demonstrating the good efficacy of treosulfan-based conditioning in the case of various haematological disorders, in both adult and paediatric patients, as well as the management of potential dermatological toxicity.⁶  

Prospects treosulfan

The large number of contributions on treosulfan-based conditioning at the EBMT reveals the great interest in this treatment option around the world. These new findings from study outcomes indicate that this conditioning therapy could potentially be made accessible to even more patient groups. The presented subgroup analysis data also highlight the well-known benefits of treosulfan-based treatment compared to the busulfan-based regimen, in particular in older and/or comorbid patients.

[1] NCT02349906, EudraCT Number: 2013-005508-33

[2] K.-W. Sykora et al. ;EBMT; 2022 [cited 2022 Mar 23]. Available from: URL:https://ebmt2022.abstractserver.com/program/#/details/presentations/999.

[3]NCT00822393, EudraCT Number: 2008-002356-18

[4] M. Stelljes et al: EBMT; 2022 [cited 2022 Mar 23]. Available from: URL: https://ebmt2022.abstractserver.com/program/#/details/presentations/84

[5] F. Stölzel et al: EBMT; 2022 [cited 2022 Mar 23]. Available from: URL: https://ebmt2022.abstractserver.com/program/#/details/presentations/90

[6] https://ebmt2022.abstractserver.com/program/#/program/1/horizontal

Find more about our common SPC.